Antibodies to Malondialdehyde‐Acetaldehyde Adduct Are Associated With Prevalent and Incident Rheumatoid Arthritis–Associated Interstitial Lung Disease in US Veterans
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42916 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Nozima Aripova und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Nebraska Medical Center, Omaha. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Arthritis, Rheumatoid, Veterans, Acetaldehyde. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense, NIGMS NIH HHS, Veterans Affairs Biomedical Laboratory Research and Development.
Abstract (Originalsprache)
Objective
The objective of this study is to determine the associations of protein‐specific anti–malondialdehyde‐acetaldehyde (MAA) antibodies with prevalent and incident rheumatoid arthritis–interstitial lung disease (RA‐ILD).
Methods
Within a multicenter, prospective cohort of US veterans with RA, RA‐ILD was validated by medical record review of clinical diagnoses, chest imaging, and pathology. Serum antibodies to MAA‐albumin, MAA‐collagen, MAA‐fibrinogen, and MAA‐vimentin (IgA, IgM, and IgG) were measured by a standardized enzyme‐linked immunosorbent assay. Associations of anti‐MAA antibodies with prevalent and incident RA‐ILD were assessed using multivariable regression models adjusting for established RA‐ILD risk factors.
Results
Among 2,739 participants with RA (88% male, mean age of 64 years), there were 114 with prevalent and 136 with incident RA‐ILD (average time to diagnosis: 6.6 years). Higher IgM anti–MAA‐collagen (per 1 SD: adjusted odds ratio [aOR] 1.28, 95% confidence interval [CI] 1.02–1.61), IgA anti–MAA‐fibrinogen (aOR 1.48, 95% CI 1.14–1.92), and IgA (aOR 1.78, 95% CI 1.34–2.37) and IgG (aOR 1.48, 95% CI 1.14–1.92) anti–MAA‐vimentin antibodies were associated with prevalent RA‐ILD. In incident analyses, higher IgA (per one SD: adjusted hazards ratio [aHR] 1.40, 95% CI 1.11–1.76) and IgM (aHR 1.29, 95% CI 1.04–1.60) anti–MAA‐albumin antibody concentrations were associated with increased ILD risk. Participants with IgA (aHR 2.13, 95% CI 1.16–3.90) or IgM (aHR 1.98, 95% CI 1.08–3.64) anti–MAA‐albumin antibody concentrations in the highest quartile had an approximately two‐fold increased risk of incident RA‐ILD. Across all isotypes, anti–MAA‐fibrinogen, anti–MAA‐collagen, and anti–MAA‐vimentin antibodies were not significantly associated with incident RA‐ILD.
Conclusion
Protein‐specific anti‐MAA antibodies to collagen, fibrinogen, and vimentin were associated with prevalent RA‐ILD. IgA and IgM anti–MAA‐albumin antibodies were associated with a higher risk of incident RA‐ILD. These findings suggest that MAA modifications and resultant immune responses may contribute to RA‐ILD pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Nebraska Medical Center, Omaha.
- University of Nebraska Medical Center and Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha.
- Pittsburgh Veterans Affairs and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- University of Kansas, Kansas City.
- University of Utah and Veterans Affairs Salt Lake City Health Care System, Salt Lake City.
- Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle.
ORCID-Profile: Nozima Aripova, Dana P Ascherman, Grant W Cannon, Katherine D Wysham, Gail S Kerr, Paul A Monach, Joshua F Baker, Jill A Poole, Ted R Mikuls, Bryant R England
Förderung
- U.S. Department of Defense
- NIGMS NIH HHS
- Veterans Affairs Biomedical Laboratory Research and Development
- Veterans Affairs Clinical Science Research and Development
- RRD VA
- BLRD VA
- CSRD VA
- Rheumatology Research Foundation
Zitieren
APA
Aripova, N., Thiele, G. M., Duryee, M. J., Hunter, C. D., Yang, Y., Roul, P., Ascherman, D. P., Matson, S. M., Kunkel, G., Cannon, G. W., Wysham, K. D., Kerr, G. S., Monach, P. A., Baker, J. F., Poole, J. A., Mikuls, T. R., & England, B. R. (2024). Antibodies to Malondialdehyde‐Acetaldehyde Adduct Are Associated With Prevalent and Incident Rheumatoid Arthritis–Associated Interstitial Lung Disease in US Veterans. Arthritis & Rheumatology. https://doi.org/10.1002/art.42916
Vancouver
Aripova N, Thiele GM, Duryee MJ, Hunter CD, Yang Y, Roul P, et al. Antibodies to Malondialdehyde‐Acetaldehyde Adduct Are Associated With Prevalent and Incident Rheumatoid Arthritis–Associated Interstitial Lung Disease in US Veterans. Arthritis & Rheumatology. 2024. doi:10.1002/art.42916
BibTeX
@article{Aripova2024,
author = {Aripova, Nozima and Thiele, Geoffrey M and Duryee, Michael J and Hunter, Carlos D and Yang, Yangyuna and Roul, Punyasha and Ascherman, Dana P and Matson, Scott M and Kunkel, Gary and Cannon, Grant W and Wysham, Katherine D and Kerr, Gail S and Monach, Paul A and Baker, Joshua F and Poole, Jill A and Mikuls, Ted R and England, Bryant R},
title = {Antibodies to Malondialdehyde‐Acetaldehyde Adduct Are Associated With Prevalent and Incident Rheumatoid Arthritis–Associated Interstitial Lung Disease in US Veterans},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42916}
}
EUVIMED